title: Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.
abstract: Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.
authors: Section of Haemato-Oncology, Institute of Cancer Research, London, UK.
authors: E
authors: E
authors: Matutes
authors: D
authors: D
authors: Oscier
authors: C
authors: C
authors: Montalban
authors: F
authors: F
authors: Berger
authors: E
authors: E
authors: Callet-Bauchu
authors: A
authors: A
authors: Dogan
authors: P
authors: P
authors: Felman
authors: V
authors: V
authors: Franco
authors: E
authors: E
authors: Iannitto
authors: M
authors: M
authors: Mollejo
authors: T
authors: T
authors: Papadaki
authors: E D
authors: ED
authors: Remstein
authors: A
authors: A
authors: Salar
authors: F
authors: F
authors: Solé
authors: K
authors: K
authors: Stamatopoulos
authors: C
authors: C
authors: Thieblemont
authors: A
authors: A
authors: Traverse-Glehen
authors: A
authors: A
authors: Wotherspoon
authors: B
authors: B
authors: Coiffier
authors: M A
authors: MA
authors: Piris
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D001853:Bone Marrow / Q000473:pathology; D002869:Chromosome Aberrations; D003131:Combined Modality Therapy; D015897:Comorbidity; D003937:Diagnosis, Differential; D019468:Disease Management; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy; D006801:Humans; D016130:Immunophenotyping; D018442:Lymphoma, B-Cell, Marginal Zone / Q000097:blood / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging / Q000379:methods / Q000592:standards; D017410:Practice Guidelines as Topic; D011379:Prognosis; D000069283:Rituximab; D013154:Spleen / Q000473:pathology; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000473:pathology / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D014408:Biomarkers, Tumor; D000069283:Rituximab